Clinical study of patients with hepatorenal syndrome treated with Lipo PGE1

谢玉桃,蒋孝华,谭德明,鲁猛厚

DOI: https://doi.org/10.3969/j.issn.1001-0025.2003.01.010

2003-01-01

Abstract:Objective:To evaluate the efficacy and safety of lipo prostaglandin E 1(Lipo PGE 1)in the treatment of severe hepatitis with hepatorenal syndrome.Methods:26 cases of severe hepatopathy with hepatorenal syndrome were randomly divided into two groups:therapy group(Lipo PGE 1)and control(spironolactone and furosemide). Each group had 13 patients. Dosage regimens were Lipo PGE 1 20 μg once a day in therapy group and spironolactone 40 mg three times a day and furosemide 40 mg twice a day in the control. Duration of treatment was 14 days.Results:Within group comparison before and after treatment:in the Lipo PGE 1 group serum creatinine reduced markedly from 195.90±40.90 μmol/L to 112.42±40.69 μmol/L and volume of urine of 24 hours increased significantly from 476.15±168.40 ml to 1569.23±776.89 ml, while in the control the above indexes only slightly improved. There was a significant difference between groups comparison(P0.01).The therapy group was better than the control in the degree of liver function improved before and after treatment(P0.01). Two groups had no severe side-effect, complication and stop-drug events during therapy.Conclusion:Lipo PGE 1 was effective and safe in the treatment of severe hepatopathy with hepatorenal syndrome.